Fujiwaki R, Takahashi K, Kitao M
Department of Obstetrics and Gynecology, Shimane Medical University, Enya-cho, Izumo, Japan.
Gynecol Oncol. 1997 May;65(2):258-64. doi: 10.1006/gyno.1997.4638.
Our purpose was to evaluate the utility of clinicopathological and biological markers prior to treatment in predicting the immediate response to chemotherapy in cervical and endometrial adenocarcinomas. Twelve patients with locally advanced cervical adenocarcinomas and 16 patients with endometrial adenocarcinomas received intraarterial neoadjuvant chemotherapy (NAC) consisting of cisplatin and doxorubicin before surgical resection. The decrease in tumor volume on magnetic resonance imaging (MRI) ([tumor volume before NAC - tumor volume after NAC]/tumor volume before NAC x 100) and the histologic response to NAC were assessed. Five factors prior to NAC (nuclear grade, pretreatment tumor volume, PCNA index, p53 protein expression, and DNA ploidy) were analyzed for correlation with the decrease in tumor volume and histologic response in cervical and endometrial adenocarcinoma, respectively. In cervical adenocarcinoma, patients with higher PCNA index tumor (> or = 40.2%) showed a significantly greater decrease in tumor volume than those with lower PCNA index (P < 0.05). In patients with endometrial adenocarcinoma, those with a smaller tumors (< 30.3 cm3) showed a significantly greater decrease than those with a larger tumors (P < 0.001). Tumors with higher PCNA index (> or = 31.5%) and negative p53 protein expression appeared to respond better than other tumors, but the difference was not statistically significant. Nuclear grade and DNA ploidy were not correlated with decrease in tumor volume either in cervical adenocarcinoma or in endometrial adenocarcinoma. Four cases of effective histologic response (2 complete responses [no microscopic residual tumor] and 2 marked responses [no macroscopic residual tumor]) were noted only in patients with endometrial adenocarcinoma who had a smaller tumor, higher PCNA index, and negative p53 protein expression. Pretreatment tumor volume and PCNA index were the only significant predictive factors (P < 0.05). Results suggest that the PCNA index in cervical and endometrial adenocarcinomas and the pretreatment tumor volume in endometrial adenocarcinoma appeared to be potentially useful in predicting the immediate response to the chemotherapy.
我们的目的是评估在治疗前,临床病理和生物学标志物对预测宫颈及子宫内膜腺癌化疗即刻反应的效用。12例局部晚期宫颈腺癌患者和16例子宫内膜腺癌患者在手术切除前接受了由顺铂和阿霉素组成的动脉内新辅助化疗(NAC)。评估了磁共振成像(MRI)上肿瘤体积的减小([NAC前肿瘤体积 - NAC后肿瘤体积]/NAC前肿瘤体积×100)以及对NAC的组织学反应。分析了NAC前的五个因素(核分级、治疗前肿瘤体积、增殖细胞核抗原(PCNA)指数、p53蛋白表达和DNA倍体)分别与宫颈和子宫内膜腺癌肿瘤体积减小及组织学反应的相关性。在宫颈腺癌中,PCNA指数较高(≥40.2%)的患者肿瘤体积减小明显大于PCNA指数较低的患者(P<0.05)。在子宫内膜腺癌患者中,肿瘤较小(<30.3 cm³)的患者肿瘤体积减小明显大于肿瘤较大的患者(P<0.001)。PCNA指数较高(≥31.5%)且p53蛋白表达阴性的肿瘤似乎比其他肿瘤反应更好,但差异无统计学意义。核分级和DNA倍体在宫颈腺癌或子宫内膜腺癌中均与肿瘤体积减小无关。仅在肿瘤较小、PCNA指数较高且p53蛋白表达阴性的子宫内膜腺癌患者中观察到4例有效的组织学反应(2例完全缓解[无微小残留肿瘤]和2例显著缓解[无肉眼残留肿瘤])。治疗前肿瘤体积和PCNA指数是仅有的显著预测因素(P<0.05)。结果表明,宫颈和子宫内膜腺癌中的PCNA指数以及子宫内膜腺癌的治疗前肿瘤体积似乎对预测化疗的即刻反应有潜在作用。